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on Drug Metabolism and PharmacokineticsProf. Aiming Yu is a tenured faculty in the Department of
Biochemistry & Molecular Medicine at University of California,
Davis (UC-Davis) School of Medicine in Sacramento, CA. He is
also a member of the Comprehensive Cancer Center at UC-Davis.
Aiming Yu obtained a B.S. degree from the Center China Normal
University in 1993 and a Ph.D. degree from the Nankai University in
1998. He then received post-doctoral trainings at University of
Washington in Seattle, WA (1998–2000) and West Virginia Uni-
versity in Morgantown, WV (2000–2002), and worked as a Research
Fellow at NCI/NIH in Bethesda, MD (2002–2004). Dr. Yu became a
faculty member at SUNY-Buffalo School of Pharmacy and Pharma-
ceutical Sciences since 2004. In 2013 Dr. Yu joined UC-Davis
School of Medicine where he also serves as Director of the PK/PD
Bioanalytical Core Facility.
Dr. Yu has long standing research interests in drug metabolism
and transport, especially the molecular mechanisms behind vari-
able drug metabolism and pharmacokinetics as well as multidrug
resistance. His original contribution includes the discovery of
role of polymorphic CYP2D6 in the O-demethylation metabolism
of psychoactive methoxyindolealkylamines, which include the16/j.apsb.2016.08.001
inese Pharmaceutical Association and Institute of Materia
an open access article under the CC BY-NC-ND licensegeneration of serotonin from 5-methoxytryptamine, highlighting
a potential “serotonin–melatonin cycle” in humans. His further
research has signiﬁcant contributions to the understanding of
indolealkylamine pharmacology and toxicology.
Large efforts in Prof. Yu laboratory have been devoted to
studying noncoding microRNA pharmacoepigenetics as well as
Cancer Pharmacology and Therapy with an ultimate goal of
developing novel noncoding RNA therapeutics. His studies have
revealed a number of miRNAs such as miR-27b, -328, -519c, and
-1291 in the regulation of CYP enzymes (e.g., CYP3A4) and ABC
transporters (e.g., ABCG2/BCRP and ABCC1/MRP1). His research
has also identiﬁed a depleted expression of miR-1291 in human
pancreatic ductal adenocarcinoma and demonstrated a tumor sup-
pressive role for miR-1291. Very recently Dr. Yu has developed a
novel robust platform to achieve a consistent, high-yield and large-
scale production of natural and biologically-active miRNA/siRNA
agents, which are distinguished from currently-used synthetic
miRNAs/siRNAs with extensive artiﬁcial modiﬁcations as well as
vector-based DNA materials requiring transcription by host cells.
Such bioengineered ncRNA agents (BERAs) represent a novel class
of biologic ncRNAs for research and therapeutics.
Dr. Yu has published over 90 peer-reviewed research and
review articles. The research in Prof. Yu lab has been supported by
several NIH R01/U01/R41 grants.
In addition to his research, Prof. Aiming Yu has been actively
involved in teaching courses in drug metabolism, pharmacology and
toxicology, and drug development, and guiding graduate students
and postdocs in research and career development. Dr. Yu vividly
provides extensive services to the scientiﬁc community which
includes various committees and advisory panels/boards. He is
currently an Editorial Board Member of Drug Metabolism and
Disposition, and Acta Pharmaceutica Sinica B. He also serves as a
standing member of NIH Xenobiotic and Nutrient Disposition and
Action (XNDA) Study Section.Medica, Chinese Academy of Medical Sciences. Production and hosting by
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Aiming Yu, Xiaobo Zhong360Dr. Xiaobo Zhong is currently a tenured Associate Professor in the
Department of Pharmaceutical Sciences at the University of
Connecticut School of Pharmacy. Dr. Zhong received his Bache-
lor’s degree in Biology from Peking University, Beijing, China in
1984 and a Ph.D. in Molecular Biology from Wageningen
University, The Netherlands in 1998. After a postdoctoral training
in human genetics and genomics in the Department of Genetics at
Yale University School of Medicine, Dr. Zhong has started his
tenure-track faculty position in the Department of Pharmacology,
Toxicology, and Therapeutics at the University of Kansas Medical
Center since 2004 and currently a tenured faculty at the University
of Connecticut after 2012.
Dr. Zhong’s research is focused on identiﬁcation of genetic and
epigenetic factors contributing to interindividual variability of drug
metabolism and development of novel approaches for personalizedmedicine and precision medicine. The major achievement Dr.
Zhong’s research has contributed to the ﬁeld includes identiﬁcation
of genetic polymorphisms in the cytochrome P450 oxidoreductase
gene and their inﬂuence on microsomal P450-mediated drug
metabolism; determination of the role of CYP3A4 mRNA alternative
30-polyadenylation in hepatocyte differentiation, liver development,
and response to drug induction; deciphering of the developmental
dynamic transcription of phase-I, phase-II drug metabolizing enzyme
and transporter genes; establishment of association of P450 gene
expression during liver development with dynamic epigenetic histone
modiﬁcations; and deﬁning of the short and long-term impacts on
drug metabolism and therapeutic efﬁcacy in adult life by drug
treatment at neonatal and infant ages.
Dr. Zhong has published over 50 peer-reviewed research and
review articles in the areas of drug metabolism with a particular focus
on P450-mediated drug metabolism. The research in Dr. Zhong's
laboratory has been supported by several NIH R01 and P01 grants.
Dr. Zhong has served as a member in several scientiﬁc societies
related to drug metabolism, including the American Society for
Pharmacology and Experimental Therapeutics (ASPET) and Interna-
tional Society for Study of Xenobiotics (ISSX) and an editorial board
member for Drug Metabolism and Disposition, Journal of Drug
Metabolism and Toxicology, Acta Pharmaceutica Sinica B, and
Frontiers in Pharmacogenetics and Pharmacogenomics. He has also
served as a reviewer in several NIH study sections for developmental
pharmacology and has been invited to present his works in many
international and national meetings as well as universities. He has
trained numerous postdoctoral fellows, Ph.D., Pharm.D., MSc, and
undergraduate students as well as visiting scholars.
